Perioperative Ivonescimab Plus Chemo for Stomach Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug (ivonescimab) given with standard chemotherapy before and after surgery for stomach or gastroesophageal junction cancer. The goal is to see if adding this treatment improves outcomes for patients whose cancer has not spread to other organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be between 18 and 75 years old
- Diagnosed with stomach or gastroesophageal junction adenocarcinoma that has spread to nearby lymph nodes but not to distant organs
- Must be in good enough health to have surgery to remove the tumor
- Haven't received any previous cancer treatments for this disease
- Must have adequate organ function, such as liver, kidney, and bone marrow
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy (DOS) plus an immunotherapy drug (Adebrelimab) given before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if the treatment shrinks the tumor and improves outcomes.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.